Who are AntiCov-220's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MVC-COV1901(3 Months), MVC-COV1901(6 Months), batch 1 of Ad5-nCoV, BNT162b6 Bivalent (Original/OMI BA.4/BA.5), Moderna mRNA-1273 COVID-19 vaccine, Lilly Bamlanivimab + Etesevimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anticov-220.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AntiCov-220 — Competitive Intelligence Brief

AntiCov-220 (AntiCov-220) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious disease.

marketed Monoclonal antibody SARS-CoV-2 spike protein Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

AntiCov-220 (AntiCov-220) — Nguyen Thi Trieu, MD. AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AntiCov-220 TARGET	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
MVC-COV1901(3 Months)	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
MVC-COV1901(6 Months)	MVC-COV1901(6 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein (S-2P)
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
BNT162b6 Bivalent (Original/OMI BA.4/BA.5)	bnt162b6-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AntiCov-220 — Competitive Intelligence Brief. https://druglandscape.com/ci/anticov-220. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab